Skip to main content

ISPOR-EU 2024 Sanofi | Regeneron | Nov 17, 2024 - Nov 20, 2024

Immunology

Sanofi is committed to advancing the science of immunology through our research and development of innovative therapies for patients with chronic, difficult-to-treat, inflammatory diseases.

Available rooms
1 of 1
  • COPD

  • Chronic Rhinosinusitis with Nasal Polyps

    Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease characterized, when uncontrolled, by bilateral nasal polyps, congestion, and impaired sense of smell, that is associated with persistent symptoms and poor quality of life.

  • Atopic Dermatitis

    Atopic dermatitis is a chronic, predominantly type 2 inflammatory disease characterized by intense itch, skin lesions, and increased risk of infections, barrier dysfunction, and poor quality of life.

  • Eosinophilic Esophagitis

    Eosinophilic Esophagitis (EoE) is a chronic type 2 inflammatory disease characterized by specific histologic changes, dysphagia, and poor quality of life due to esophageal scarring and narrowing.

  • Asthma

    Asthma is predominately a chronic type 2 inflammatory disease. When uncontrolled, asthma is characterized by impaired lung function, severe exacerbations, recurrent symptoms, and poor quality of life.

  • Prurigo Nodularis

    Prurigo Nodularis (PN) is a chronic, inflammatory skin condition characterized by intense pruritus, stinging/burning, and papulonodular lesions. Uncontrolled PN can have substantial physical, mental, emotional, and socio-economic effects on patients’ quality of life.

  • Chronic inducible cold urticaria

  • Chronic Pruritus of Unknown Origin